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Background: Systemically administered dexmedetomidine (DEX), a selective α2 adrenergic receptor (α2-AR) agonists,
produces analgesia and sedation. Peripherally restricted α2-AR antagonist could block the analgesic effect of systemic
DEX on neuropathic pain, with no effect on sedation, indicating peripheral analgesic effect of DEX. Tetrodotoxin-
resistant (TTX-R) sodium channel Nav1.8 play important roles in the conduction of nociceptive sensation. Both α2-AR
and Nav1.8 are found in small nociceptive DRG neurons. We, therefore, investigated the effects of DEX on the Nav1.8
currents in acutely dissociated small-diameter DRG neurons.
Results: Whole-cell patch-clamp recordings demonstrated that DEX concentration-dependently suppressed TTX-R
Nav1.8 currents in small-diameter lumbar DRG neurons. DEX also shifted the steady-state inactivation curves of Nav1.8
in a hyperpolarizing direction and increased the threshold of action potential and decrease electrical and chemical
stimuli-evoked firings in small-diameter DRG neurons. The α2-AR antagonist yohimbine or α2A-AR antagonist BRL44408
but not α2B-AR antagonist imiloxan blocked the inhibition of Nav1.8 currents by DEX. Immunohistochemistry results
showed that Nav1.8 was predominantly expressed in peripherin-positive small-diameter DRG neurons, and some of
them were α2A-AR-positive ones. Our electrophysiological recordings also demonstrated that DEX-induced inhibition of
Nav1.8 currents was prevented by intracellular application of G-protein inhibitor GDPβ-s or Gi/o proteins inhibitor
pertussis toxin (PTX), and bath application of adenylate cyclase (AC) activator forskolin or membrane-permeable
cAMP analogue 8-Bromo-cAMP (8-Br-cAMP). PKA inhibitor Rp-cAMP could mimic DEX-induced inhibition of
Nav1.8 currents.
Conclusions: We established a functional link between α2-AR and Nav1.8 in primary sensory neurons utilizing the
Gi/o/AC/cAMP/PKA pathway, which probably mediating peripheral analgesia of DEX.
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Dexmedetomidine (DEX), a potent and highly selective
agonist of the alpha 2 adrenergic receptors (α2-ARs) with
more favorable pharmacokinetic properties than clonidine
(another commonly used α2-AR agonist) is approved for
the adult intensive care unit use as sedative infusion by
the US Food and Drug Administration in 1999. Three
α2-ARs (α2A-, α2B- and α2C-ARs) have been cloned,
and all of which are coupled to inhibitory G proteins
[1] and play an important role in the control of pain.
The α2-ARs have a diffuse distribution in the nervous
system, including in primary afferents, spinal dorsal horn
and brain stem [2-5]. Systemically administered α2-AR ag-
onists produce anti-nociceptive effects in humans and
animals, suggesting that the α2-AR may be involved in
anti-nociception at the supraspinal, spinal and peripheral
levels [6-9]. Our previous study showed that intrathecal
DEX significantly suppressed monoarthritis-induced thermal
hyperalgesia and glial activation in spinal level [10]. How-
ever, intrathecal or intracerebroventricular administration of
DEX produces dose-dependent sedation [11]. Peripherally
restricted α2-AR antagonist could block the analgesic effect
of systemic DEX on neuropathic pain, with no effect on sed-
ation, indicating peripheral analgesic effect of DEX [7].
Evidence has emerged that the effects on ion channels
may be an important mechanism underlying DEX-induced
peripheral anti-nociception [12,13]. Previous studies have re-
vealed that changes in function of voltage-gate sodium chan-
nels in nociceptive primary sensory neurons participate in
the development of peripheral hyperexcitability that occurs
in neuropathic and inflammatory pain conditions [14,15].
Among them, the tetrodotoxin-resistant (TTX-R) sodium
channel Nav1.8 primarily expressed by small- and medium-
sized dorsal root ganglion (DRG) neurons [16,17], substan-
tially contributes to the upstroke of action potential in these
neurons [18]. Nav1.8-null mice displayed a pronounced in-
crease in threshold to noxious mechanical stimuli and a
slight decrease in nociceptive thermoreception as well as
delayed development of inflammatory hyperalgesia [19].
Likewise, functional knockdown of Nav1.8 in rats reduces
hyperalgesia and allodynia in neuropathic pain and inflam-
matory pain models [14,20,21]. Several G-protein-coupled
receptors (GPCRs)-mediated second-messenger cascades in-
cluding PKA, PKC and MAPKs have been shown to regulate
Nav1.8 sodium channels [14,22]. In the present study, we in-
vestigated whether the peripheral DEX-induced analgesia
might in part arise from the suppressed activation of TTX-R
sodium channel Nav1.8 currents via binding to its GPCR
α2-ARs in small-diameter DRG neurons.
Results
Recording of Nav1.8 currents in DRG neurons
Double immunofluorescence revealed that Nav1.8 was
predominantly expressed in peripherin-positive small-diameter DRG neurons (Figure 1A). In the present study,
all recordings were performed in small-diameter (<25 μm)
DRG neurons. With existence of TTX (500 nM) in ex-
ternal solution, TTX-resistant (TTX-R) sodium currents
were recorded in most (170 out of 223) of the small-
diameter DRG neurons. As our previous reported, the
membrane potential was held at −60 mV to inhibit
Nav1.9 currents, leaving the Nav1.8 currents intact [22].
The family of Nav1.8 currents was generated with a
voltage-clamp protocol (holding at -60 mV, depolarizing
steps from -55 mV to +40 mV, 50 ms, 5 mV increment,
Figure 1B). According to the current–voltage relationship
(Figure 1C), we selected -15 mV to elicit Nav1.8 currents
in most of the recordings (Figure 1D). The peak amplitude
of Nav1.8 currents was stable during the recordings.
Effects of DEX on Nav1.8 currents in small DRG neurons
Application of DEX in different doses (0.03, 0.1, 0.3, 1, 3
and 30 μM) dose-dependently reduced the peak amplitude
of Nav1.8 currents in small DRG neurons within 1 min
and washed out within 5 min (Figure 2A and B). One-way
ANOVA analysis revealed a significant effect of DEX treat-
ment (F6,66 = 23.885, p < 0.001). The ED50 was calculated
to be 0.92 μM (95% CI: 0.77–1.68). The maximal inhibi-
tory effect (36.51 ± 5.39%) was induced by 3 μM DEX.
A higher concentration of DEX (30 μM) failed to in-
duce more powerful inhibition (34.56 ± 2.7%), indicating a
“ceiling effect” at a concentration of 3 μM (Figure 2C).
The effects of DEX on the activation and inactivation
properties of Nav1.8 currents were studied using the ap-
propriate voltage protocols. As described above, a voltage-
clamp protocol consisted of 50 ms depolarizing steps from
-55 mV to +40 mV with 5 mV increment was used to de-
termine the activation of Nav1.8 channels. No shift in
the voltage-dependent activation curve was observed in
DEX-treated group compared with control one (Figure 3A).
The half-maximal activation potential (V1/2 activation)
was −27.30 ± 2.13 mV (n = 7) and −28.17 mV ± 0.73 mV
(n = 7) in the absence and presence of 3 μM DEX, respect-
ively. Steady-state inactivation of Nav1.8 channel was de-
termined at a series of membrane potentials from −60 mV
to −20 mV with 5 mV increment for 500 ms and a follow-
ing test potential of −15 mV. DEX caused a left shift
toward the hyperpolarizing potential of the steady-
state inactivation curve (Figure 3B). The V1/2 inactivation
was −40.49 ± 2.49 mV (n = 9) of the control and −45.39 ±
2.65 mV (n = 9) of DEX treatment, respectively.
DEX reduced Nav1.8 currents via α2A-AR
DEX was a selective alpha 2 adrenergic receptor (α2-AR)
agonist. To address whether the attenuation of Nav1.8
currents induced by DEX application was mediated by
α2-ARs, the effect of yohimbine, an α2-ARs antagonist,
on inhibitory effects of DEX on Nav1.8 currents was
Figure 1 Isolation of TTX-resistant Nav1.8 currents in small-diameter DRG neurons. (A) Double immunofluorescence reveals the expression
of Nav1.8 in peripherin-positive small-diameter DRG neurons. (B) Representative I-V curve family of currents recorded in the presence of 500 nM
TTX. Cells were depolarized to a variety of potentials (−55 mV to +40 mV) from a holding potential of -60 mV, to elicit Nav1.8 currents. (C) I-V curve of
Nav1.8 currents shown in (B). (D) Representative traces of Nav1.8 currents elicited by a single pulse of −15 mV.
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per se inhibited Nav1.8 currents (Figure 4A). Pretreatment
of DRG neurons with 3 μM yohimbine, a concentration
to antagonize DEX-induced membrane hyperpolarization
mediated by α2-ARs in rat hypothalamic neurons [23],
DEX-induced suppression of the Nav1.8 currents was
significantly blocked (Figure 4B and C). The peak dens-
ities of Nav1.8 currents in yohimbine (3 μM) plus DEX
(3 μM)-treated group was significantly greater than that
in DEX-treated group (One-way ANOVA, F3, 26 = 5.451,
p < 0.01). Moreover, we examined the effect of BRL44408Figure 2 DEX dose-dependently inhibits Nav1.8 currents. (A, B) Typica
recorded pre- (control) and post- (DEX) perfusion of DEX and wash out. (C
currents were measured after a 1-min application of different concentration(a preferential α2A-AR antagonist) on DEX-induced inhib-
ition of Nav1.8 currents. Pre-incubation of BRL44408
(1 μM) alone did not affect the peak densities of Nav1.8
currents, but significantly blocked DEX-induced suppres-
sion of Nav1.8 currents (Figure 4D and F). Given that
BRL44408 may also be able to block α2B-AR at a higher
dose, we further examined the effect of α2B-AR antagonist
imiloxan on DEX-induced inhibition of Nav1.8 currents.
Neither basal Nav1.8 currents nor DEX-induced sup-
pression was influenced by incubation of imiloxan (3 μM)
(Figure 4E and F). These data indicated that DEXl traces illustrating the Nav1.8 currents in small-diameter DRG neurons
) Dose-effect curve of DEX-induced inhibition of Nav1.8 currents. The
s of DEX.
Figure 3 Effect of DEX on the steady-state activation and inactivation curves of Nav1.8. (A) DEX (3 μM) did not shift voltage-dependent
activation curve. (B) DEX (3 μM) shifted the steady-state inactivation curve in a hyperpolarizing direction.
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Also, the colocalization of Nav1.8 with α2A-AR in
DRG small-diameter neurons provided a cellular basis
for the involvement of α2A-AR in the DEX modulating
Nav1.8 currents (Figure 4G).
Gi/o-proteins participate in DEX-induced Nav1.8 currents
inhibition
Given α2-ARs act through G-proteins, we examined the
effect of GDPβ-s, a G protein inhibitor, on DEX-induced
rapid suppression of Nav1.8 currents in small DRG neu-
rons. Inclusion in pipette solution of GDPβ-s (1 mM)
did not impair Nav1.8 activation. On the other hand, the
inhibition of Nav1.8 currents by DEX was completely
abolished (Figure 5A and C) (One-way ANOVA, F3,38 =
12.757, p < 0.01).
α2A-ARs are generally known to coupled to the inhibi-
tory Gi proteins [24] through which they inhibit adenyl-
ate cyclase (AC) activity. Therefore, we examined whether
DEX-induced inhibition of Nav1.8 currents occurs via Giproteins. As shown in Figures 5B and C, pertussis toxin
(PTX, 1 μg/ml), an irreversible inhibitor of Gi/o-proteins,
significantly prevented the Nav1.8 currents amplitude
change induced by DEX (One-way ANOVA, F3,30 =
15.765, p < 0.01). Inclusion in pipette solution of PTX
(1 μg/ml) did not change Nav1.8 currents amplitude
(Figure 5B and C).
Because Gi proteins inhibit the catalytic activity of AC,
which catalyzes cAMP production, the Gi-mediated sup-
pression of Nav1.8 currents can be the consequence of
decreased levels of intracellular cAMP and a concomitant
reduction in PKA-dependent phosphorylation of Nav1.8.
Here, we used Rp-cAMP, 8-Br-cAMP and forskolin to
examine the effects of AC-cAMP-PKA pathway on the
Nav1.8 currents. Incubate with PKA inhibitor Rp-cAMP
(50 μM) for 5 min, Nav1.8 currents were significantly
suppressed. Co-application of 3 μM DEX did not cause a
further reduction of the currents amplitudes (Figure 5D
and E). Moreover, 5-min pretreatment of DRG neurons
with 8-Br-cAMP (500 μM) a membrane-permeable cAMP
Figure 4 α2-AR mediates inhibition of DEX on Nav1.8 currents. (A) The effects of different doses of yohimbine (α2-AR antagonist) on Nav1.8
currents. (B, C) pre-incubation of yohimbine (3 μM) for 30 min blocked the inhibitory effect of DEX (3 μM) on Nav1.8 currents. *p < 0.05. (D-F)
DEX-induced inhibition of Nav1.8 currents were completely blocked by pre-incubation of α2A-AR antagonist BRL44408 (1 μM) but not by α2B-AR
antagonist imiloxan (3 μM). (G) Immunofluorescence micrographs of two adjacent sections from a DRG (L5) after incubation with α2A-AR
antibody and Nav1.8 antibody. Arrowhead indicates coexistence between α2A-AR and Nav1.8 in the same neurons.
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slight increase in Nav1.8 currents amplitude (Figure 5 F-I).
Although the increase did not reach statistical significance,
it totally removed the inhibitory effect of DEX on Nav1.8
currents (Figure 5G and I).
Effect of dexmedetomidine on excitability of DRG neurons
Nav1.8 is the main contributor to the upstroke of action
potentials in small-diameter DRG neurons [18]. Thus,modulation of this channel by DEX should influence the
excitability of DRG neurons. We applied 10 ms step de-
polarizing currents pulse to evoke action potentials. In
13 of 23 neurons tested, DEX 3 μM significantly increase
the injected currents threshold to evoke action poten-
tials from 37.5 ± 4.97 pA to 61.88 ± 5.78 pA before and
after exposure to DEX respectively (paired t-test, p < 0.01)
(Figure 6A and B). Moreover, by injection of maximum
currents pulse (500 ms, 200 pA), action potential firing
Figure 5 Involvement of Gi/o proteins/AC/cAMP/PKA pathway in DEX-induced inhibition of Nav1.8 currents. (A-C) Loading neurons with
1 mM GDPβ-s or PTX completely abolished the inhibitory effect of DEX on Nav1.8 currents. *p < 0.05. (D, E) Pre-incubation PKA inhibitor Rp-cAMP
(50 μM) inhibited Nav1.8 currents. Co-application of DEX did not cause a further reduction of the current amplitudes. *p < 0.05. (F, G) Pre-incubation
cAMP analogues 8-Br-cAMP (500 μM) prevented DEX-induced inhibition of Nav1.8 currents. (H, I) Pre-incubation AC activator forskolin (0.1 μM)
prevented DEX-induced inhibition of Nav1.8 currents.
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by DEX treatment (Figure 6C and E). DEX-induced inhibi-
tory effect on action potential firing can be mimicked by
selective α2A-AR agonist guanfacine (30 μM) (Figure 6D
and E). Similarly, 0.5 μM capsaicin-induced action potentials
were also significantly blocked by DEX (Figure 6F and G).
Discussion
In this study, we demonstrated that selective α2-AR agon-
ist dexmedetomidine (DEX) reduced Nav1.8 currents insmall-diameter acutely dissociated DRG neurons. We also
showed that DEX decreased excitability of small sensory
neurons by increasing the activation threshold and de-
creasing the action potential firing. This inhibition of
Nav1.8 currents was completely blocked by the selective
α2A-AR antagonist, suggesting that α2A-AR might be
directly involved in DEX-induced changes in Nav1.8 ac-
tivity. We also found that the PTX-sensitive Gi/o proteins/
AC/cAMP/PKA signaling cascade is primarily responsible
for the activation of Nav1.8 currents in response to DEX
Figure 6 Effect of DEX on the action potential threshold and firing rate of DRG neurons. (A) In current clamp model, depolarizing current
pulse required to evoke an action potential in a DRG neuron before and after application of DEX (a = 25 pA, b = 30 pA, c = 40 pA, d = 45 pA).
(B) DEX (3 μM) reduced the amount of currents required to evoke action potential. (C, D) Firing response of DRG neurons to a 200 pA
depolarizing current pulse (500 ms) before and after application of DEX (C) and selective α2A-AR agonist guanfacine (D). (E) Summary data
indicate the inhibitory effects of DEX and guanfacine on firing rate in DRG neurons. (F, G) Current clamp recording showing suppression of
capsaicin-induced action potential firing by DEX (3 μM). *p < 0.05; **p < 0.01.
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anism of DEX analgesia.
TTX-R sodium channel primarily expresses in DRG
nociceptors [25,26]. In the two distinct TTX-R sodium
channel isoforms Nav1.8 and Nav1.9, Nav1.8 likely mediates
the majority of TTX-R currents. Accumulating evidence
points up that TTX-R sodium channel plays an important
role in peripheral pain processing [27]. Nociceptive signals
evoke a dynamic change of TTX-R sodium channel, for
example, chronic compression (CCD) of the DRG [15,28]
or local inflammation of the DRG by the application of
zymosan [29] and subcutaneous injection of carrageenan
[30] or complete Freund’s adjuvant (CFA) [31] produces
an increase in TTX-R sodium currents in small DRG
neurons. Either the physiological or pathological pain
was alleviated in the Nav1.8-null mice or Nav1.8 knock-
down rats [14,27,32,33]. Peripheral inflammation or nerve
injury has been shown to upregulate Nav1.8 expression in
nociceptive DRG neurons [34,35]. Blockade of Nav1.8
sodium channel by A-803467, a potent and selective
Nav1.8 sodium channel blocker, could inhibit nerve injury-
induced mechanical allodynia and inflammation-induced
thermal hyperalgesia [36].
Given that both α2-AR and Nav1.8 are found in small
nociceptive DRG neurons [4,5,37], and α2A-AR and
Nav1.8 co-localized in the same small DRG neurons, we
propose that stimulation of α2-AR in sensory neurons
may lead to an attenuation of the painful symptoms of
hypersensitivity via the inhibition of Nav1.8 channel ac-
tivity. Consistently, application of DEX concentration-
dependently decreased the current density of Nav1.8 in
small DRG neurons and shifted the voltage-dependence
of steady-state inactivation curve for Nav1.8 in the hyper-
polarizing direction, which could result in a lower thresh-
old for Na+ channel inactivation. DEX also increased the
threshold of action potential and decreased firing rate in
small DRG neurons. Despite of the previous reports that
yohimbine did not alter DEX-induced inhibition of TTX-
R Na+ currents in small DRG neurons [12] and voltage-
gated Na+ currents in NG108-15 cells [13], the present
study showed that 3 μM yohimbine, a concentration to
antagonize DEX-induced membrane hyperpolarization
mediated by α2-ARs in rat hypothalamic neurons [23],
completed blocked DEX-induced suppression of the
Nav1.8 currents, suggesting an involvement of α2-ARs
in DEX effect. Considering the affinity of yohimbine for
α1-ARs, serotonin and dopamine receptors [38], inhib-
ition of high dose yohimbine per se on Nav1.8 currents
may relate to the interaction of yohimbine with these
receptors.
Although three subtypes of the α2-ARs mRNAs were
expressed in the rat DRGs [5,39,40], α2B-AR mRNA was
only found in small numbers of neuron profiles [5,41],
and following peripheral nerve injury, α2A-AR and α2C-AR mRNA levels increased and decreased, respectively
[5,40]. Also, the immunohistochemical analysis showed
that α2A-AR and α2C-AR proteins in DRG neurons was
respectively increased and decreased after chronic con-
striction injury of sciatic nerve, whereas no α2B-AR neu-
rons were detected in either normal or nerve injury DRG
[42]. Moreover, α2A-AR rather than α2C-AR in the super-
ficial layers of spinal dorsal horn was observed in the ter-
minals of capsaicin-sensitive and substance P-containing
primary afferent fibers [2]. Degeneration of TRPV1 affer-
ent terminals, the level of α2A-AR, but not α2C-AR, was
largely reduced in primary afferent terminals [43]. Our
present study further showed co-localization of α2A-AR-
and Nav1.8-like immunoreactivity in small DRG neurons.
DEX-induced inhibition of Nav1.8 currents was prevented
by pretreatment of BRL44408, a preferential α2A-AR
antagonist, but not of imiloxan, a α2B-AR antagonist. In
addition to Nav1.8, other cation channels, for example,
TRPM8 may also participate in α2A-AR-mediated nocicep-
tive inhibition. Stimulation of α2A-AR inhibited TRPM8 in
DRG neurons [44]. Taken together, these findings suggest
that the α2A-AR subtype represents the most likely candi-
date in DRG neurons to be involved in the modulation of
nociceptive information.
Our data strongly suggest that DEX inhibits Nav1.8 cur-
rents in a Gi/o proteins/AC/cAMP/PKA signaling-dependent
manner in small DRG neurons. Specifically, we showed
that preventing Gi/o recruitment by PTX treatment blocked
DEX-induced inhibition of Nav1.8 current density, and
PKA inhibitor mimicked the effect of DEX through the re-
ceptor. In support of this, it has been also reported that
blockade of PKA activity inhibited the baseline Nav1.8
currents in small-diameter nodose ganglion neurons [45].
Consistent with the general notion that stimulation of
α2A-AR by DEX brings about Gi-mediated inhibition of
AC and reduction of intracellular cAMP levels, AC ac-
tivator forskolin and cAMP analogues 8Br-cAMP com-
pletely reversed DEX-induced inhibition of Nav1.8 currents.
These findings suggest that the classical AC/cAMP/PKA
signaling pathway resulting from the α2-ARs-mediated acti-
vation of PTX-sensitive Gi/o proteins is involved in the
regulation of Nav1.8 by DEX.
Conclusions
DEX attenuated TTX-R sodium channel Nav1.8 currents
in small-diameter DRG neurons via α2A-AR/Gi/o/AC/
cAMP/PKA cascade, which probably constitutes a mech-
anism of peripheral DEX analgesia.
Materials and methods
Animals
Male adult (100–150 g) Wistar rats were obtained from
the Experimental Animal Center, Shanghai Medical
College of Fudan University, China. Rats were on a 12 h
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received food and water ad libitum. All experiments pro-
tocols were permitted by the Shanghai Animal Care and
Use Committee and followed the policies issued by the
International Association for the Study of Pain on the use
of laboratory animals. All efforts were made to minimize
animal suffering and reduce the numbers of animals used.
Preparation of DRG neurons
Animals were anesthetized with ether and rapidly decap-
itated. DRGs from L4-L6 lumbar segments were removed
and immediately transferred onto DMEM (Gibco, Life
Technologies, Grand Island, NY, USA) on ice. The ganglia
were minced with fine spring scissors and treated with col-
lagenase (2.67 mg/ml, type IA, Sigma, St. Louis, MO) and
trypsin (1 mg/ml, type I, Sigma) in DMEM saturated with
CO2/O2 mixed gas at 37°C for 35 min. After wash with
standard external solution (in mM, 150 NaCl, 5 KCl, 2
CaCl2, 1 MgCl2, 10 HEPES, and 10 glucose, adjusted to
pH 7.4 with NaOH) three times, the ganglia were then
gently triturated using fine fired-polished Pasteur pipettes.
The dissociated DRG neurons were plated onto 10-mm
diameter coverslips in the 3.5 cm culture dishes and incu-
bated with standard external solution. Each culture dishes
contained three or four coverslips and all the experiments
were performed within 2–8 h after plating.
Patch-clamp recordings
Whole-cell voltage-clamp and current-clamp recordings
of DRG neurons were performed at room temperature
(RT, 23 ± 1°C) with an EPC-9 amplifier (HEKA Elektronik,
Lambrecht/Pfalz, Germany). Stimulation protocols and
data acquisition were controlled by the software Pulsefit
8.5 (HEKA Elektronik). All of the recordings were per-
formed in small-diameter (15–25 μm) DRG neurons with
resting membrane potentials more negative than −50 mV.
Microelectrodes (N51A borosilicate glass, Sutter Instru-
ments) with a resistance of 2–6 MΩ were pulled using a
P97 puller (Sutter Instruments). The pipette solution con-
tained (in mM): 140 CsF, 1MgCl2, 1 EGTA, 2.5 Na2ATP,
10 HEPES, pH was adjusted to 7.2 with CsOH. Seals
(1–10 GΩ) between the electrode and the cells were
established. After the whole-cell configuration was estab-
lished, the cell membrane capacitance and series resistance
were compensated (>80%). Leak currents were subtracted
using the online P/4 protocol. The data were sampled at
10 kHz and low-passed at 2 kHz. For Nav1.8 recordings,
the external solution contained (in mM): 32 NaCl, 20
TEA-Cl, 105 choline-Cl, 1 MgCl2, 1 CaCl2, 0.1 CdCl2,
10 HEPES, 0.0005 TTX and 10 glucose, adjusted to
pH 7.4 with NaOH. For current-clamp recordings, the
electrode solution was changed to: 140 KCl, 1 MgCl2,
0.5 CaCl2, 5 EGTA, 10 HEPES, 2.5 Na2ATP, pH was ad-
justed to 7.2 with KOH. The external solution was changedto: 150 NaCl, 5 KCl, 2.5 CaCl2, 1 MgCl2, 10 HEPES, pH
was adjusted to 7.4 with NaOH. DRG neurons were held
at −60 mV and Nav1.8 currents were evoked by de-
polarizing pulses to -15 mV. The activation and inacti-
vation properties of Nav1.8 currents were studied using
the appropriate voltage protocols. The voltage-clamp proto-
col consisted of 50 ms depolarizing steps from -55 mV
to +40 mV with 5 mV increment was used to determine
the activation of Nav1.8 channels. The Boltzmann function
of the form GNa / GNamax = 1 / {1 + exp [(Vm1/2 - Vm) / k]}
was used to describe the voltage dependence of activation
and half activation potential was obtained. Steady-state
inactivation of Nav1.8 channel was determined at a
series of membrane potentials from −60 mV to −20 mV
with 5 mV increment for 500 ms and a following test
potential of −15 mV. The steady-state inactivation curve
was fitted by the Boltzmann function INa / INamax = 1 / (1 +
exp [(V - Vm1/2) / k]), where INamax is the maximal peak
current,V is the prepulse membrane potential.
Drugs
All the drugs were purchased from Sigma (St. Louis, MO,
USA). The drugs were dissolved in normal saline as stock
solutions. All of the stock solutions were stored at −20°C
or −80°C until use. Working concentrations of the drugs
were prepared on the day of the experiment from the
stock solutions. The drug dosages were selected based on
previous reports and our preliminary studies. Dexmedeto-
midine was applied continuously for 1 min closed to
cells via ALA-VM8 perfusion system (ALA Scientific
Instruments, Westbury, NY). Yohimbine and BRL44408
were applied to the chamber 30 min before and during
the perfusion of dexmedetomidine (DEX). Rp-cAMP,
8-Br-cAMP and forskolin were applied to chamber
5–10 min before and during the DEX perfusion. GDPβ-s
and PTX were applied in the pipette internal solution.
Immunohistochemistry
Animals were given an overdose of urethane and were
then transcardially perfused with normal saline followed
by 4% paraformaldehyde in 0.1 M phosphate buffer
(pH 7.4, 4°C). DRGs (L4–L6 segments) were removed
and postfixed in the same fixative for 2 h at 4°C and then
immersed in a 10–30% gradient of sucrose in phosphate
buffer for 24–48 h at 4°C for cryoprotection. DRGs were
embedded in OCT compound, cut in a cryostat (Leica
1900, Leica) at 7 μm (to study Nav1.8 and α2A-AR coexist-
ence) or 14 μm thickness and mounted onto gelatin
coated slides. The sections were placed in a humid cham-
ber and processed for immunohistochemistry. The sec-
tions were blocked with 10% donkey serum in 0.01 M PBS
(pH 7.4) with 0.3% Triton X-100 for 1 h at RT. For Nav1.8
and peripherin (a small-diameter DRG neuronal marker)
double immunofluorescence, the sections were incubated
Gu et al. Molecular Brain  (2015) 8:15 Page 10 of 11with a mixture of rabbit anti-Nav1.8 (1:1000; Alomone)
with mouse anti-peripherin (1:2000; Millipore) overnight
at 4°C, followed by a mixture of Alex Flour 488- and
Alex Flour 546-conjugated secondary antibodies (1:200;
Invitrogen) for 2 h at 4°C. For detecting Nav1.8 and
α2A-AR coexistence, two adjacent sections (7 μm) was
respectively incubated with rabbit anti-Nav1.8 (1:1000)
and rabbit anti-α2A-AR (1:100; Alomone) primary anti-
bodies in PBS with 1% normal donkey serum and 0.3%
Triton X-100 overnight at 4°C, followed by incubation
within Alex Flour 546- and Alex Flour 488-conjugated
secondary antibodies for 2 h at 4°C, respectively. All of
the slides were coverslipped with 50% glycerin in 0.01 M
PBS and then examined with an Olympus FV1000 con-
focal laser scanning microscope (Olympus). Images were
acquired using FV10-ASW software. The specificities of
the immunostaining were verified by observing no immu-
nostaining after omitting the primary antibodies, which re-
sulted in the disappearance of the immunostaining signals.
The specificities of the primary antibodies were verified by
a preabsorption experiment. Sections were first incubated
overnight with a mixture of Nav1.8 or α2A-AR primary
antibody and the corresponding blocking peptide (5:1
blocking peptide: primary antibody), followed by incu-
bation with a secondary antibody. The immunostaining
signals were abolished after absorption.
Data analysis
The data were presented as means ± standard error of
mean (SEM). Statistical comparisons were performed using
Student’s t-test, paired t-test and one-way ANOVA followed
by post hoc Student-Newman-Keuls test. In all cases,
p < 0.05 was considered statistically significant.
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